A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What are the Global Challenges?

Abstract:

BACKGROUND AND OBJECTIVES:Generic substitution has been introduced in most countries in order to reduce costs and improve access to drugs. However, regulations and the generic drugs available vary between countries. It is the prescriber or dispenser of the drug who is the final decision maker. Nevertheless, physicians' and pharmacists' perceptions of generic drug use are not well documented to date. This study presents a systematic review of physicians' and pharmacists' perspectives on generic drug use worldwide. METHODS:A systematic literature search was performed to retrieve all articles published between 2002 and 2012 regarding physicians' and/or pharmacists' experiences with generic drugs and generic substitution. RESULTS:Of 1322 publications initially identified, 24 were eligible for inclusion. Overall, the studies revealed that physicians and pharmacists were aware of the cost-saving function of generic drugs and their role in improving global access to drugs. Nevertheless, marked differences were observed between countries when studying physicians' and pharmacists' perceptions of the available generic drugs. In less mature healthcare systems, large variations regarding, for example, control routines, bioequivalence requirements, and manufacturer standards were reported. A lack of reliable information and mistrust in the efficacy and quality were also mentioned by these participants. In the most developed healthcare systems, the participants trusted the quality of the generic drugs and did not hesitate to offer them to all patients regardless of socioeconomic status. In general, pharmacists seemed to have better knowledge of the concept of bioequivalence and generic drug aspects than physicians. CONCLUSIONS:The present study indicates that physicians and pharmacists are aware of the role of generic drugs in the improvement of global access to drugs. However, there are marked differences regarding how these health professionals view the quality of generic drugs depending on the maturity of their country's healthcare system. This can be attributed to the fact that developed healthcare systems have more reliable public control routines for drugs in general as well as better bioequivalence requirements concerning generics in particular.

authors

Toverud EL,Hartmann K,Håkonsen H

doi

10.1007/s40258-014-0145-2

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

S35-45

eissn

1175-5652

issn

1179-1896

journal_volume

13 Suppl 1

pub_type

杂志文章,评审
  • Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.

    abstract::One focus of health economics is the trade-off between limited resources and the (health) needs of a community. Cost-effectiveness analysis (CEA), while being one of the most accepted evaluation methodologies in health economics, does not account for many important costs and benefits of health care interventions. Some...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Bridges JF

    更新日期:2003-01-01 00:00:00

  • Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes.

    abstract:BACKGROUND:When pharmaceuticals are administered based on patient characteristics (for example weight or body surface area), an amount of product will be unused and must be disposed of. This wastage represents inefficiency and can distort decision making. METHODS:We present a method for the analysis of optimum fill vo...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0444-0

    authors: Hatswell AJ,Porter JK

    更新日期:2019-06-01 00:00:00

  • Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review.

    abstract:OBJECTIVES:The aim of this review is to assess the current state of empirical research regarding the effectiveness of national pricing regulations of the patent-protected market for prescription pharmaceuticals. Effectiveness is understood to be the capacity of policies to have a desired impact on outcomes, such as hea...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0437-z

    authors: Wettstein DJ,Boes S

    更新日期:2019-04-01 00:00:00

  • Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System.

    abstract:BACKGROUND:Early awareness and alert systems have been established in many countries but evidence on their ability to accurately prioritize new medicines (for early assessment) is limited. OBJECTIVE:The purpose of this study was to assess whether the Swedish Early Awareness and Alert System identified and prioritized ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0434-2

    authors: Eriksson I,von Euler M,Malmström RE,Godman B,Wettermark B

    更新日期:2019-02-01 00:00:00

  • Current and future economic burden of osteoporosis in New Zealand.

    abstract:BACKGROUND:Osteoporosis is recognized as a serious health condition in developed as well as developing countries. There are no accurate estimates of the extent of the burden of osteoporosis in New Zealand. The purpose of this study was to estimate the economic burden of osteoporosis in New Zealand using data from inter...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11531500-000000000-00000

    authors: Brown P,McNeill R,Leung W,Radwan E,Willingale J

    更新日期:2011-03-01 00:00:00

  • The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations.

    abstract:BACKGROUND:Immunization rates for human papillomavirus (HPV) infections remain low among teenagers despite strong evidence of the effectiveness of vaccines. Physician recommendations of the vaccine are far from universal. Several states have enacted policies that mandate HPV vaccination or distribute educational materi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0225-6

    authors: Moghtaderi A,Adams S

    更新日期:2016-06-01 00:00:00

  • U.S. and International In-Hospital Costs of Extracorporeal Membrane Oxygenation: a Systematic Review.

    abstract:CONTEXT:The in-hospital costs of extracorporeal membrane oxygenation (ECMO) have not been well established. OBJECTIVE:To evaluate the in-hospital costs of ECMO technology in both US and non-US settings for all patient types. DATA SOURCES:Systematic review of English-language articles, using the PubMed, Embase, Web of...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-015-0170-9

    authors: Harvey MJ,Gaies MG,Prosser LA

    更新日期:2015-08-01 00:00:00

  • The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience.

    abstract:BACKGROUND:There are limited economic evaluations comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for multi-vessel coronary artery disease (MVCAD) in contemporary, routine clinical practice. OBJECTIVE:The aim was to perform a cost-effectiveness analysis comparing CABG and ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0407-5

    authors: Ariyaratne TV,Ademi Z,Huq M,Rosenfeldt F,Duffy SJ,Parkinson B,Yap CH,Smith J,Billah B,Yan BP,Brennan AL,Tran L,Reid CM

    更新日期:2018-10-01 00:00:00

  • Utility Estimates of Disease-Specific Health States in Prostate Cancer from Three Different Perspectives.

    abstract:OBJECTIVE:To develop a statistical model generating utility estimates for prostate cancer specific health states, using preference weights derived from the perspectives of prostate cancer patients, men at risk for prostate cancer, and society. METHODS:Utility estimate values were calculated using standard gamble (SG) ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0282-x

    authors: Gries KS,Regier DA,Ramsey SD,Patrick DL

    更新日期:2017-06-01 00:00:00

  • Cost of Medicare for All: Review of the Estimates.

    abstract::This paper critically evaluates the estimates of the cost of Medicare for All (M4A) in the USA. Six studies that estimate the 1-year total cost of M4A in the USA are reviewed. These studies find that M4A would increase national health spending by as much as 16.9% or decrease it by 20.0%, representing a range of estima...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-021-00636-6

    authors: Nyman JA

    更新日期:2021-01-25 00:00:00

  • Virtual Touch™ Quantification to Diagnose and Monitor Liver Fibrosis in Hepatitis B and Hepatitis C: A NICE Medical Technology Guidance.

    abstract::Virtual Touch™ Quantification (VTq) is a software application used with Siemens Acuson ultrasound scanners to assess the stiffness of liver tissue. The National Institute for Health and Care Excellence (NICE) Medical Technologies Advisory Committee (MTAC) selected VTq for evaluation and invited the company to submit c...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-016-0277-7

    authors: Summers JA,Radhakrishnan M,Morris E,Chalkidou A,Rua T,Patel A,McMillan V,Douiri A,Wang Y,Ayis S,Higgins J,Keevil S,Lewis C,Peacock J

    更新日期:2017-04-01 00:00:00

  • Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

    abstract:BACKGROUND:Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0050-0

    authors: Zeidler J,Mahlich J,Greiner W,Heres S

    更新日期:2013-10-01 00:00:00

  • Supplier-induced demand: reconsidering the theories and new Australian evidence.

    abstract::This paper reconsiders the evidence and several of the key arguments associated with the theory of supplier-induced demand (SID). It proposes a new theory to explain how ethical behaviour is consistent with SID. The purpose of a theory of demand and one criterion for the evaluation of a theory is the provision of a pl...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.2165/00148365-200605020-00003

    authors: Richardson JR,Peacock SJ

    更新日期:2006-01-01 00:00:00

  • The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.

    abstract:BACKGROUND:In Slovenia during the period 2000-2010, the number of years of potential life lost before the age of 70 years per 100,000 population under 70 years of age declined 25 %. OBJECTIVE:The aim of this study was to test the hypothesis that pharmaceutical innovation played a key role in reducing premature mortali...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-014-0144-3

    authors: Lichtenberg FR

    更新日期:2015-04-01 00:00:00

  • Why does economic analysis in health care not get implemented more? Towards a greater understanding of the rules of the game and the costs of decision making.

    abstract::Despite recent initiatives across a number of countries to institutionalise the use of economic evaluation in the assessment of new technologies, the evidence suggests that, to date, the impact of economic analysis on health sector decision making in practice has been low. This paper proposes that incentive compatibil...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Jan S

    更新日期:2003-01-01 00:00:00

  • A Systematic Review of the Association Between Hospital Cost/price and the Quality of Care.

    abstract:BACKGROUND:Limited empirical evidence exists regarding the effect of price changes on hospital behavior and, ultimately, the quality of care. Additionally, an overview of the results of prior literature is lacking. OBJECTIVE:This study aims to provide a synthesis of existing research concerning the relationship betwee...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-020-00577-6

    authors: Jamalabadi S,Winter V,Schreyögg J

    更新日期:2020-10-01 00:00:00

  • The use of research abstracts in formulary decision making by the Joint Oncology Drug Review of Canada.

    abstract:BACKGROUND AND OBJECTIVE:Opinions on the use of research abstracts in policy decision making are conflicting. We sought to evaluate the influence of research abstracts in guiding decisions of the Joint Oncology Drug Review of Canada (JODR), which conducts clinical and economic reviews of new cancer treatment drugs for ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11530510-000000000-00000

    authors: Weizman AV,Griesman J,Bell CM

    更新日期:2010-01-01 00:00:00

  • Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

    abstract:OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-019-00496-1

    authors: Vreman RA,Geenen JW,Hövels AM,Goettsch WG,Leufkens HGM,Al MJ

    更新日期:2019-12-01 00:00:00

  • Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.

    abstract:BACKGROUND:In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. OBJECTIVE:The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. METHODS:In the MONE...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11592220-000000000-00000

    authors: Gazzard B,Hill A,Anceau A

    更新日期:2011-07-01 00:00:00

  • Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.

    abstract:BACKGROUND:Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE:To estimate the costs of treatment including the resources used by patients wit...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0272-z

    authors: Kostić M,Djakovic L,Šujić R,Godman B,Janković SM

    更新日期:2017-02-01 00:00:00

  • Demand for outpatient healthcare: empirical findings from rural India.

    abstract:BACKGROUND:Price, income and health status are likely to affect the demand for healthcare in developing countries, and their quantitative effects are unclear in the literature. Some studies report that prices are not important determinants, while others conclude that prices are important determinants of the demand for ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256160

    authors: Sarma S

    更新日期:2009-01-01 00:00:00

  • Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

    abstract:BACKGROUND:It is estimated that annually 300 000 cases of rotavirus-induced gastroenteritis (RVGE) occur in children aged up to 5 years in France. A two-dose vaccine against rotavirus infection (RIX4414; Rotarix, GlaxoSmithKline), has been shown to be highly effective against severe RVGE. OBJECTIVE:This study evaluate...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256134

    authors: Standaert B,Parez N,Tehard B,Colin X,Detournay B

    更新日期:2008-01-01 00:00:00

  • The infrastructure of obesity and the obesity epidemic: implications for public policy.

    abstract::If present increases in the rate of obesity persist, by 2015 half of the population in the US could be obese. This article presents the case that the reason for the epidemic is an 'infrastructure of obesity' that fuels the phenomenon. To control this epidemic, public policy in general and health policy in particular n...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200504030-00001

    authors: Stanton KR,Acs ZJ

    更新日期:2005-01-01 00:00:00

  • Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.

    abstract:BACKGROUND:Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. OBJECTIVE:To estimate the cost effectivene...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11535520-000000000-00000

    authors: Logman JF,Heeg BM,Herlitz J,van Hout BA

    更新日期:2010-01-01 00:00:00

  • Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.

    abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-015-0180-7

    authors: Shields GE,Bates AE,Chapman AM

    更新日期:2015-10-01 00:00:00

  • A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.

    abstract::This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative an...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-014-0150-5

    authors: Hu S,Zhang Y,He J,Du L,Xu M,Xie C,Peng Y,Wang L

    更新日期:2015-08-01 00:00:00

  • Explaining the health costs associated with managing intracranial aneurysms in Italy.

    abstract:BACKGROUND:The clinical management of intracranial aneurysms is debated in many countries because of the associated disability risk and costs. Therefore, estimating the costs and explaining their variability will provide important information for decision makers. OBJECTIVE:We aimed to evaluate the acute and post-acute...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0041-1

    authors: Calciolari S,Torbica A,Tarricone R

    更新日期:2013-08-01 00:00:00

  • The Memokath-051 Stent for the Treatment of Ureteric Obstruction: A NICE Medical Technology Guidance.

    abstract::Memokath-051 is a thermo-expandable, nickel-titanium alloy spiral stent used to treat ureteric obstruction resulting from malignant or benign strictures. The National Institute for Health and Care Excellence (NICE) selected Memokath-051 for evaluation. The company, PNN Medical, claimed Memokath-051 has clinical superi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-018-0389-3

    authors: Eaton Turner E,Jenks M,McCool R,Marshall C,Millar L,Wood H,Peel A,Craig J,Sims AJ

    更新日期:2018-08-01 00:00:00

  • The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial.

    abstract:BACKGROUND:Chronic obstructive pulmonary disease (COPD) affects approximately 3 million people in the UK. An 8-week pulmonary rehabilitation (PR) course is recommended under current guidelines. However, studies show that initial benefits diminish over time. OBJECTIVE:We present here an economic evaluation conducted al...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40258-015-0199-9

    authors: Burns DK,Wilson EC,Browne P,Olive S,Clark A,Galey P,Dix E,Woodhouse H,Robinson S,Wilson A

    更新日期:2016-02-01 00:00:00

  • Genetic health technology and economic evaluation: a critical review.

    abstract::The aim of the review is to establish whether, on the basis of previous published evidence, current accepted guidance for health economic evaluation needs to be adapted to evaluate healthcare based on use of genetic information. Online literature search strategies were designed (using PubMed and the NHS Economic Evalu...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.2165/00148365-200605010-00004

    authors: Jarrett J,Mugford M

    更新日期:2006-01-01 00:00:00